An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis (Q30410564)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis |
scientific article |
Statements
1 reference
An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis (English)
1 reference
Yibin Kang
Menashe Bar-Eli
Suzanne A Eccles
Kent Hunter
Lynn M Matrisian
1 July 2009
1 reference